Clarity Pharmaceuticals (ASX:CU6): What Does the CLARIFY Trial Milestone Mean for Its Clinical Pipeline?

Aditi Sarkar

29 October 2026 03:28 PM AEDT

Clarity Pharmaceuticals (ASX:CU6): What Does the CLARIFY Trial Milestone Mean for Its Clinical Pipeline?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Clarity Pharmaceuticals (ASX:CU6) completed dosing of its 383-participant target in Phase III CLARIFY.
CLARIFY and AMPLIFY diagnostic study readouts are anticipated in H1 calendar 2027.
The SECuRE main-group recruitment target of 16 participants was met in October 2026.
FY26 net loss reached AUD 107.2 million, with AUD 178.3 million of liquid assets at 30 June 2026.

Clarity Pharmaceuticals Limited develops targeted copper-based radiopharmaceuticals for cancer imaging and treatment, with particular emphasis on prostate cancer. The company reported completion of dosing for the planned 383 participants in its registrational Phase III CLARIFY study in late October 2026, following a separate recruitment milestone in its SECuRE treatment program earlier in the month. During trading on 29 October 2026, Clarity Pharmaceuticals (ASX:CU6) was quoted around AUD 1.63, with an intraday gain of approximately 4%, while the next clinical reporting stages remained central to its operational calendar. The market quotation is distinct from the clinical announcements.

Company Business

Clarity Pharmaceuticals (ASX:CU6) operates as a clinical-stage developer rather than a commercial pharmaceutical manufacturer. Its proprietary SAR technology attaches radioactive copper isotopes to targeting molecules, creating radiopharmaceuticals for diagnostic imaging and therapeutic applications. Copper-64 is used in imaging candidates, while copper-67 is used in investigational treatments. The company’s development portfolio includes SAR-bisPSMA for prostate cancer, SARTATE for neuroendocrine tumours and SAR-Bombesin for cancer imaging applications.

The CLARIFY and AMPLIFY diagnostic trials involve centres in the United States and Australia, and SECuRE is conducted in the United States. These studies examine different clinical uses, from locating disease before prostate surgery to detecting recurrence and assessing radioligand therapy. Clarity Pharmaceuticals (ASX:CU6) is also preparing manufacturing and distribution arrangements, including a commercial manufacturing agreement announced in April 2026 with Nucleus RadioPharma for copper-64 SAR-bisPSMA.

Recent Development

On 27 October 2026, Clarity announced that the target 383 participants had received study dosing in CLARIFY, its Phase III trial of copper-64 SAR-bisPSMA in patients with high-risk prostate cancer ahead of radical prostatectomy. The trial evaluates diagnostic sensitivity and specificity for pelvic lymph node disease, assessed using histopathology, with scans undertaken on the same day or approximately 24 hours after administration. Reaching the dosing target does not establish efficacy or constitute regulatory approval; participant follow-up and data analysis remain necessary.

The company expects topline CLARIFY results in the first half of calendar 2027, a period that also includes its anticipated AMPLIFY readout in biochemically recurrent prostate cancer. On 8 October, Clarity Pharmaceuticals (ASX:CU6) reported achievement of the SECuRE cohort expansion main-group recruitment target of 16 participants. That study assesses copper-67 SAR-bisPSMA in metastatic castration-resistant prostate cancer. Recruitment for participants receiving the therapy alongside enzalutamide was continuing at the time of the announcement.

SECuRE results reported in August covered 19 participants treated at an 8 GBq dose level. The company reported PSA reductions of at least 50% in 63% of evaluable participants. These are early-stage findings from a small group and cannot establish outcomes in a larger controlled study.

Financial Performance and Sector Context

Clarity Pharmaceuticals (ASX:CU6) reported an FY26 net loss of AUD 107.2 million, compared with AUD 64.3 million in FY25. Research and development expenditure increased to AUD 91.1 million from AUD 66.9 million as clinical trials and commercial-readiness work expanded. Corporate and commercialisation expenses were AUD 27.8 million, compared with AUD 11.7 million, while finance income and research and development tax incentives contributed to reported income.

Net cash used in operating activities was AUD 92.5 million for the year ended 30 June 2026, against AUD 54.8 million the prior year. At year-end, the group held AUD 57.2 million in cash equivalents and AUD 121.0 million in term deposits, representing AUD 178.3 million in liquid assets. Net assets stood at AUD 186.1 million. As a pre-commercial developer, the company relies on available capital to finance trials, regulatory preparation and supply-chain investment ahead of any potential product revenues.

For radiopharmaceutical developers, manufacturing consistency, isotope supply, diagnostic trial performance and regulatory review affect commercial-readiness decisions. In this context, trial progress is an operating milestone but not a substitute for approved products or recurring sales.

Risks to Consider

Clarity Pharmaceuticals (ASX:CU6) faces clinical trial, regulatory, manufacturing and funding risks. Diagnostic accuracy endpoints may not meet regulatory requirements, while treatment results from small patient groups may differ in larger studies. Patient follow-up, site execution and manufacturing scale-up can alter timelines and expenditure. Continuing operating cash outflows could reduce available liquidity, and currency movements may affect reported balances and expenses.

What to Watch Next

The immediate clinical milestones are the expected H1 calendar 2027 CLARIFY and AMPLIFY topline findings, followed by decisions on potential US regulatory submissions. Updates on the SECuRE combination arm, additional patient observations and planning for a future registrational treatment trial also warrant attention. Clarity Pharmaceuticals (ASX:CU6) has scheduled its annual general meeting for 25 November 2026. Future cash-flow reports will indicate the pace of clinical and manufacturing spending.

Key Insights

Clarity has advanced its diagnostic pipeline by completing CLARIFY target dosing and has expanded patient enrolment in SECuRE. FY26 accounts show increasing trial-related expenditure and operating cash use, alongside liquid assets of AUD 178.3 million at 30 June 2026. The principal measurable developments for Clarity Pharmaceuticals (ASX:CU6) are clinical readouts, safety observations, regulatory preparation and the resources available to complete remaining development work.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.